Fingolimod. Mitsubishi Pharma/Novartis.
FJ Dumont - Idrugs: the Investigational Drugs Journal, 2005 - europepmc.org
FJ Dumont
Idrugs: the Investigational Drugs Journal, 2005•europepmc.orgMitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active
immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of
transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis.
Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts
as a sphingosine-1-phosphate receptor agonist.
immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of
transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis.
Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts
as a sphingosine-1-phosphate receptor agonist.
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
europepmc.org